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Results
•246 patients (France (39%), USA 
(29%), Romania (18%), UK (10%), 
Germany (4%)) and 12 caregivers
(Romania (42%), France (33%), USA 
(17%), Germany (8%)).
•Average annual cost per patient was 
€38,820 of which 47% accounted for 
DMTs, 41.3% for indirect costs due to 
productivity losses, 5.5% for  non-
medical costs (formal/informal care), 
3.9% for inpatient care and 2.9% for 
ambulatory care (Figure1).
•Mean annual productivity loss per 
caregiver amounted up to €31,155. 
•Country differences existed on total 
costs (p<0.001), direct medical costs 
(p<0.001),  indirect costs (p<0.05) and 
EQ-5D-5L utilities (p<0.001) which 
ranged from 0.77 in Germany to 0.49 in 
France (Figure 2).
•Mean patient and caregiver EQ-5D-5L 
index and VAS scores were 0.60 
(±0.12) and 63, and 0.70 (±0.19) and 
72 respectively. 
•Individuals treated earlier had a trend 
towards lower total (€38,185 vs. 
€42,058, p>0.05), DMT (€18,942 vs. 
€20,044, p>0.05) and indirect (€15,390 
vs.€18,521, p>0.05) costs and a higher 
EQ-5D VAS score (65 vs.62, p>0.05) 
than those receiving no or late DMT. 
Methods
•Two web-surveys (Qualtrics ®) of individuals with MS and their caregivers. 
•14 patient associations (whether at national or supra-national level) were invited 
to cascade the surveys to their network of patients and caregivers.
•Patient survey collected data on;  i) Demographics, ii) Time between diagnosis 
and treatment, iii) Healthcare resource utilisation (incl. consumption of DMTs), iv) 
Productivity losses, v) QoL (EuroQoL 5-domain; EQ-5D-5L), EQ-5D-5L VAS and 
vi) Physical disability (Barthel Index).
•Caregiver survey collected data on; i) Demographics, ii)Productivity losses,  
iii) QoL (EuroQoL 5-domain; EQ-5D-5L), EQ-5D-5L VAS and iv) Emotional 
burden (Zarit Burden Interview).
•Microsoft® Excel 2010 was used to generate descriptive statistics and SPSS   
(v.21) to test for country and treatment group differences (using one way ANOVA 
and independent samples t-test respectively).
Background & Objectives
Multiple Sclerosis (MS) is the second most common 
cause of neurological disability and highest per capita 
costs among all other neurological disorders [1]. Early 
Disease Modifying Therapy (DMT) (i.e. within 12 
months of a single neurological attack with MRI 
enhancing lesions) is proposed as a preventative 
strategy against disability accumulation in MS patients 
[2,3].
We aimed to estimate the socioeconomic burden and 
Quality of Life (QoL) of MS patients and evaluate the 
role of  early DMT towards better disease outcomes. 
Conclusions & Future directions 
MS introduces a significant global economic burden for societies, with 
DMT costs and work productivity losses representing 88% of the total 
average annual costs. Early DMT initiation yielded promising results 
in terms of reducing the overall burden of the disease.
 In the absence of long-term, real world data about the cost-
effectiveness of receiving DMT earlier in the course of the disease, 
when to initiate treatment and which DMT to use are still to be 
determined. 
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Figure 1. Average annual cost (€ 2014-15) per patient between countries and 
between early and late treated individuals.  
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Figure 2. Mean patient utility, utility loss and disability between countries and 
between early and late treated individuals  
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